CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 3,410	$ 3,889
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[4]	1,218	1,545
Asset write-offs and impairments	[4]	45	155
TCJA impact	[4],[5]	0	(131)
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	[4]	(6)	0
Deferred taxes from continuing operations	[4]	109	(60)
Share-based compensation expense	[4]	64	185
Benefit plan contributions in excess of expense/income	[4]	(248)	(151)
Other adjustments, net	[4]	123	(236)
Other changes in assets and liabilities, net of acquisitions and divestitures	[4]	(1,581)	(3,498)
Net cash provided by operating activities	[4]	3,133	1,698
Investing Activities
Purchases of property, plant and equipment	[4]	(463)	(460)
Purchases of short-term investments	[4]	(2,551)	(1,402)
Proceeds from redemptions/sales of short-term investments	[4]	3,257	3,601
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[4]	(416)	5,941
Purchases of long-term investments	[4]	(22)	(84)
Proceeds from redemptions/sales of long-term investments	[4]	152	44
Acquisitions of intangible assets	[4]	(32)	(158)
Other investing activities, net	[4]	4	67
Net cash provided by/(used in) investing activities	[4]	(71)	7,550
Financing Activities
Proceeds from short-term borrowings	[4]	5,302	609
Principal payments on short-term borrowings	[4]	(7,551)	(1,766)
Net proceeds from short-term borrowings with original maturities of three months or less	[4]	3,207	2,032
Proceeds from issuance of long-term debt	[4]	1,241	4,942
Principal payments on long-term debt	[4]	(2,181)	(3,004)
Purchases of common stock	[4]	0	(8,865)
Cash dividends paid	[4]	(2,105)	(2,045)
Proceeds from exercise of stock options	[4]	124	126
Other financing activities, net	[4]	(237)	(495)
Net cash used in financing activities	[4]	(2,200)	(8,467)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[4]	(15)	12
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[4]	846	792
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[4]	1,350	1,225
Cash and cash equivalents and restricted cash and cash equivalents, end	[4]	2,196	2,018
Cash paid (received) during the period for:
Income taxes	[4]	239	235
Interest paid	[4]	472	385
Interest rate hedges	[4]	$ (11)	$ (33)

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] Amounts may not add due to rounding.

[4] Amounts may not add due to rounding.

[5] As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for the three months ended March 31, 2019 was favorably impacted by approximately $131 million, primarily as a result of additional guidance issued by the U.S. Department of Treasury.